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Abstract The globular domain IVa from the short arm region
of mouse laminin K5 chain was obtained by recombinant
production and shown to be a cell-adhesive substrate and to bind
KVL3 integrin in solid-phase assays. These interactions were
blocked by RGD peptides and a restricted panel of anti-integrin
antibodies. The two RGD sequences present in K5IVa were
shown by site-directed mutagenesis to make different contribu-
tions to cell adhesion but were equivalent in binding KVL3
integrin. A quantitative radioimmuno-inhibition assay was
established based on domain K5IVa which demonstrated distinct
amounts of K5 chain in various tissues, particularly in vessel
walls. There it could play a role in angiogenesis steps requiring
RGD-dependent integrins. ß 2001 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
The laminins represent a large protein family and are in-
volved in basement membrane assembly and major cell^ma-
trix interactions. They are composed of disul¢de-bonded K, L,
Q chains and 14 isoforms of these chains have been extensively
or partially characterized [1,2]. The largest variant known so
far is the K5 chain with about 3700 residues [3] which is
present in laminin-10 (K5L1Q1) and laminin-11 (K5L2Q1) [4^
7]. These laminins are already expressed during early somite
stages of mouse development [8] and can be detected in many
tissues during further development and also in the adult stage
[4,7,9^11]. An important function of laminin K5 chain is also
strongly indicated from gene targeting in mice which die at
embryonic days 14^17 with massive failures in neural tube
closure, digit septation and glomerulogenesis [8,12].
A major function impaired in the K5 chain knock-out mice
could be integrin-mediated cell adhesion which, as shown
from studies with laminin-10 and -11, involves the K3L1 and
K6L1 integrins [5,6,13]. This implicated, in analogy to other
laminin isoforms [1,2], binding of the receptors to the C-ter-
minal LG modules of the K5 chain. A cell-adhesive pepsinized
form of laminin-10/11, however, did not recognize these in-
tegrins [14]. Additional cellular interactions could include hep-
arin binding epitopes as shown for C-terminal and N-terminal
recombinant fragments of the K5 chain [15,16] and the luther-
an blood group glycoprotein [17,18]. A further possible inter-
action site could be one or both of the two RGD sequences
present in domain IVa within the short arm of the laminin K5
chain [3]. Such RGD recognition sequences are frequently
found in other extracellular proteins including ¢bronectin
and vitronectin and have the ability to bind to various integ-
rins [19]. RGD sequences are rarely found in laminins and
only a cryptic binding site has so far been identi¢ed in the
mouse laminin K1 chain [20,21].
In the present study we have examined these possibilities by
recombinant production of domain IVa which folded into a
globular structure. This fragment promoted cell adhesion
mediated by RGD-dependent integrins with di¡erent contri-
butions made by the two RGD sequences as shown by site-
directed mutagenesis.
2. Materials and methods
2.1. Sources of proteins, antibodies and cells
Laminin-1 in complex with nidogen-1 was obtained from a mouse
tumor basement membrane [22] and vitronectin was puri¢ed from
human plasma [23]. Synthetic peptides were prepared by our internal
facilities (Dr. L. Moroder) and characterized by mass spectrometry.
Inhibitory monoclonal antibodies against human L1 (AIIB2), K5
(BIIG2) and K6 (GoH3) integrin subunits were kindly supplied by
Drs. C. Damsky and A. Sonnenberg. Other inhibitory monoclonal
antibodies were obtained from commercial sources (Dianova, Ham-
burg; Biomol) and are identi¢ed in Table 1. The sources of cell lines
used have been previously identi¢ed [20].
2.2. Production and characterization of recombinant protein domains
An expression vector for mouse laminin domain K5IVa was ampli-
¢ed by RT-PCR using RNA from embryonic endothelial cells [24]
(kindly supplied by Antonis Hatzopoulos) as template and the 5P
primer GTCAACTAGTTACCCGCTGCTTCTGTTTCGGG and 3P
primer GTCACTCGAGCTAGGGGACACATCGGCCTAGGAAG.
After restriction with SpeI/XhoI the cDNA was ligated into the epi-
somal expression vector pCEP-Pu containing the BM-40 signal pep-
tide [25]. Mutations were introduced by fusion PCR [26]. These vec-
tors were used to transfect human kidney 293-EBNA cells and to
collect serum-free conditioned medium [25]. For numbering of se-
quence positions [3] we added 83 more residues to the N-terminus
(data bank accession number AJ293593) including the K5 chain signal
peptide.
Serum-free medium (1 l) was passed over a DEAE cellulose column
(2.5U8 cm) equilibrated in 0.05 M Tris^HCl, pH 8.6 followed by
elution with a linear 0^0.4 M NaCl gradient (400/400 ml). The
K5IVa fragments and mutants eluted around 0.2 M NaCl and were
obtained in puri¢ed form by molecular sieve chromatography on a
Superose 12 column (HR 16/50, Pharmacia) equilibrated in 0.2 M
ammonium acetate, pH 8.6). Production and puri¢cation of the
mouse laminin K1 chain fragment K1IVa has been previously de-
scribed [21].
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Electrophoresis in SDS gels, Edman degradation on a 473 se-
quencer (Applied Biosystems) and amino acid analysis for determin-
ing protein and hexosamine concentrations followed established pro-
tocols. Rotary shadowing was used prior to electron microscopy [27].
2.3. Cell adhesion and integrin binding assays
Cell adhesion to coated micro-well plates, staining of adherent cells
with crystal violet and colorimetry have been described [28]. Inhibitors
were used over a 100-fold concentration range and added to the cells
prior to seeding to the coated wells. Integrin KVL3 was puri¢ed by
a⁄nity chromatography from human placenta and used as immobi-
lized ligand in solid-phase binding assays [29].
2.4. Immunological assays
Immunization of rabbits, a⁄nity puri¢cation of antibodies, ELISA
and radioimmunoassays followed standard protocols. Adult mouse
tissue extracts were prepared with neutral bu¡er containing 10 mM
EDTA followed by the same bu¡er containing detergents [30] and
used in the radioimmuno-inhibition assay speci¢c for K5IVa. These
extracts were also analyzed by inhibition assays speci¢c for laminin
fragments K1VI/V [31] and a similar assay for K2VI/V (T. Sasaki, R.
Giltay, U. Talts, R. Timpl and J.F. Talts, submitted). All these ex-
tracts were examined in duplicate using three di¡erent dilutions which
showed at the most a variability not exceeding 20^30% of the mean.
Indirect immuno£uorescence staining with a⁄nity-puri¢ed antibodies
(5 Wg/ml) was performed on cryostat sections of adult mouse tissues
[32]. Control incubations with normal rabbit IgG gave negative re-
sults.
3. Results
Domain K5IVa corresponds to position 1631^1863 of
mouse laminin K5 chain and was produced by human 293-
EBNA cells transfected with an episomal expression vector
[25]. These cells secreted the recombinant fragment K5IVa in
reasonable amounts (4^7 Wg/ml/day) into serum-free culture
medium which was used for puri¢cation by conventional
chromatography. The puri¢ed fragment showed a single 31
kDa band in SDS gel electrophoresis (Fig. 1A) and a single
N-terminal sequence APLVTR(C)F(C)F with the ¢rst four
residues being derived from the signal peptide cleavage region
of the vector. Rotary shadowing electron microscopy showed
small globular structures (Fig. 1B) indicating the proper fold-
ing of fragment K5IVa.
Fragment K5IVa corresponds to an L4 module type of lam-
inins with the disul¢de bond connectivities Cys1^3, Cys2^4,
Cys5^6 and Cys7^8 and a 200 residue long globular insert in
loop b between Cys2 and 4 [20,21]. It contains two potential
cell binding RGD sites [17] within the sequences 1718-
HSETQRGDIF in the center of loop b and 1834-CPA-
NYRGDSC between Cys5 and 6 [3]. These RGD sites are
changed to PGD and TGD, respectively, in the analogous
domain IVa of laminin K3B chain [33] and we used these
substitutions to produce the K5IVa mutants R1723P and
R1839T and the double mutant R1723P/R1839T. These mu-
tants were puri¢ed and showed the same 31 kDa band as
K5IVa (R1723P) and in addition a 34 kDa band for
R1839T and the double mutant (Fig. 1A). The increase in
molecular mass was due to the generation of an N-glycosyla-
tion site (1837-NYT) as shown by a content of three glucos-
amines not found in the wild-type. All three mutants were
indistinguishable from wild-type K5IVa when examined by
ELISA with an antiserum against K5IVa (data not shown).
The activity of these RGD sites was initially examined in
cell adhesion assays as shown for B16F10 melanoma cells
(Fig. 2A) and revealed a distinct dose^response pro¢le with
half-maximal attachment for K5IVa at coating concentrations
of 1^2 Wg/ml. Since a native laminin-10 was not available, a
comparison was made with laminin-1 which showed a similar
activity but with higher plateau levels (Fig. 2A). Similar dose^
response pro¢les for both substrates were also observed with
Table 1
Inhibition of cell adhesion to laminin domain K5IVa by monoclonal
antibodies to integrins and synthetic peptides
Inhibitors HT1080 cells A375 cells
Antibodies Maximal inhibition in %
Anti-L1 (AIIB2) 100 55
Anti-K3 (P1B5) 30 0
Anti-K6 (GoH3) 0 0
Anti-KV (AMF7) 0 30
Anti-KVL5 (P1F6) 80 40
Anti-K5 (BIIG2) nt 70
Peptides Maximal inhibition in % and IC50 (WM)
GRGDS 90 (3) 100 (4)
RGES 0 (s 500) 0 (s 500)
ETQRGDI 90 (6) 100 (10)
ANYRGDS 90 (15) 100 (10)
Inhibitions were examined by dose^response pro¢les starting with
antibody dilutions strongly inhibiting cell adhesion in other adhe-
sion assays and with 500 WM peptides. IC50 refers to concentrations
required for half-maximal inhibition. nt = not tested.
Fig. 1. Characterization of recombinant fragment K5IVa and mu-
tants by SDS gel electrophoresis (A) and rotary shadowing electron
microscopy (B). Lanes in A were loaded with wild-type K5IVa (lane
1), mutant R1723P (2), mutant R1839T (3,4) and the double mutant
R1723P/R1839T (5,6). The latter two mutants were examined after
separating their 31 and 34 kDa bands by molecular sieve chroma-
tography. Wild-type K5IVa is shown in B.
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human ¢brosarcoma HT-1080 and melanoma A375 cells and
rat schwannoma RN22 cells. However, several other cell lines
such as human A431, Saos-2 and HBL-100 and rat Rugli
glioma failed to adhere to the K5IVa substrate.
The speci¢city of interactions was further studied in inhibi-
tion assays with monoclonal antibodies against human integ-
rins and with synthetic RGD peptides (Table 1). This demon-
strated moderate to complete inhibition by anti-L1 antibodies
and variable levels of inhibition with antibodies against KVL5
integrin and KV or K5 subunits. However, antibodies against
K3 and K6 integrin subunits showed either no or only a mar-
ginal e¡ect. A more uniform 90^100% inhibition, which was
half-maximal at 3^15 WM peptide, was achieved with
GRGDS, ETQRGDI and ANYRGDS, the latter two corre-
sponding to authentic K5IVa sequences. This inhibition was
speci¢c since no e¡ect was observed with 100-fold higher con-
centrations of synthetic RGES (Table 1).
The relative contributions of the two RGD sites to cell
adhesion were further studied by the K5IVa mutants described
above. This showed for A375 cells (Fig. 2B) a distinct reduc-
tion in the activity of mutant R1723P which was further aug-
mented in the double mutant. The loss of activity was dis-
tinctly less in the mutant R1839T where a ¢ve-fold increase in
the coating concentration was necessary to obtain a compa-
rable reaction as with K5IVa. Similar pro¢les as shown in Fig.
2B were observed with three more cell lines. In a second test
we used puri¢ed RGD-dependent KVL3 integrin [29] in solid-
phase binding assays (Fig. 3). This showed for K5IVa a dis-
tinct binding pro¢le with half-maximal binding achieved at 0.5
nM and was thus comparable to the binding of vitronectin
(0.3 nM). The two mutants showed a 10^20-fold lower activity
while no binding was observed with the double mutant up to
a concentration of 50 nM.
A broad distribution of laminins containing the K5 chain
during developmental and adult stages was previously shown
by analyzing mRNA expression and antibody staining of tis-
sues [4,7^11]. Because quantitative immunological assays were
not available, a more precise correlation to the tissue contents
of other laminin K chains was impossible. We have now gen-
erated a rabbit antiserum against K5IVa which showed a good
titer (1:2500) in ELISA and no cross-reaction with the related
laminin K1IVa chain fragment at 1:50 dilution. This high
speci¢city was con¢rmed by a radioimmuno-inhibition assay
for K5IVa which showed inhibition by K5IVa in a dose-de-
pendent manner with 0.2 nM K5IVa required for 50% inhibi-
tion. No inhibition was observed with 1000-fold higher con-
centrations of K1IVa and several more unrelated laminin
fragments (data not shown).
The radioimmunoassay was also inhibited by EDTA and
detergent extracts of adult mouse tissues which showed the
same dose^response pro¢le as the K5IVa reference inhibitor.
This set the stage for a quantitative evaluation which showed
K5 chain contents in the range of 3^159 pmol/g wet tissue
(Table 2). This was 3^78% of the concentration of either K1
or K2 chain that dominate a particular tissue. The relative
contents of K5 chain was, however, low in heart and skeletal
muscle which contain large amounts of K2 but only negligible
amounts of K1 chain. A⁄nity-puri¢ed antibodies against
K5IVa were also examined by immuno£uorescence staining
(examples shown in Fig. 4) and showed a localization to
many basement membranes in kidney, lung and skin and to
a large variety of small and larger vessels. A restricted staining
of vessels was, however, observed in heart and skeletal muscle
Fig. 2. Adhesion pro¢les of mouse melanoma B16F10 (A) and hu-
man melanoma A375 cells (B) to fragment K5IVa and K5IVa mu-
tants. Wells were coated with K5IVa (a), mutants R1723P (P) and
R1839T (O), the double mutant R1723P/R1839T (b) and laminin-1
(E).
Fig. 3. Solid-phase binding assay to immobilized KVL3 integrin.
Soluble ligands used were vitronectin (a), laminin fragment K5IVa
(b) and its mutants R1723P (O), R1839T (R) and R1723P/R1839T
(E).
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in agreement with a relatively low content of K5 chain in these
tissues (Table 2).
4. Discussion
The successful recombinant production of laminin fragment
K5IVa demonstrated as shown before for K1IVa [21] that
laminin L4 type modules represent an autonomous unit capa-
ble of folding into a globular structure. Domain K5IVa was
also shown to be a cell-adhesive substrate as anticipated from
the presence of two RGD sequences [3]. These interactions
can be mediated by several RGD-dependent integrins includ-
ing K5L1, KVL3, KVL5 and possibly KVL1 as shown by inhi-
bition and direct binding assays. Since both RGD sequences
are conserved in the human laminin K5 chain (K. Tryggvason,
personal communication) it is likely that they will have a
similar cell-adhesive activity which may be conserved among
most mammalian species. This conservation does not exist for
the Drosophila laminin K chain which corresponds to K5 [34].
There is also no conservation in the mouse laminin K3B chain
[33] which, as shown here for the K5 double mutant, will
abolish cell adhesiveness and KVL3 integrin binding. Thus it
appears that the laminin K5 chain is unique among all other
laminin chain isoforms known so far in binding to RGD-de-
pendent integrins.
Depending on the assay used, the activity of both RGD
sequences in domain K5IVa did not seem to be always equiv-
alent. There was no signi¢cant di¡erence in the binding to
puri¢ed KVL3 integrin while cell adhesion seemed to be stron-
ger with the 1723-RGD than the 1839-RGD site. This could
re£ect the topological positions of both sites being either in
the center of the globular b loop or constrained in the short c
loop between a disul¢de bridge which may have a di¡erent
impact on the binding of soluble versus cell membrane-bound
integrins. Yet, it could also be due to di¡erent a⁄nities of
individual integrins which are more complex in the cell adhe-
sion assay and also include a substantial fraction of L1 integ-
rins.
The only other cell-adhesive RGD site of laminins identi¢ed
so far has been located to the mouse K1 chain but pepsin
digestion is necessary to generate an active fragment P1 [20].
This fragment was adhesive for all four cell lines binding to
K5IVa but also for cells which did not adhere to K5IVa in-
dicating a di¡erent repertoire of integrins involved in binding.
Furthermore, the binding of puri¢ed KVL3 integrin to laminin
P1 was much weaker than to vitronectin [29] unlike the bind-
ing to K5IVa observed in this report. The RGD in the K1
chain is located in a small disul¢de-bonded loop next to do-
main K1IVa but does not seem to be very active in cell adhe-
sion and KVL3 integrin binding as shown with a correspond-
ing recombinant fragment indicating that it is still masked by
the globular domain K1IVa [21]. It is furthermore not known
whether proteolytic activation of the RGD site of laminin-1
occurs in tissues and this RGD is also not conserved in the
human laminin K1 chain. The biological signi¢cance of this
cell adhesion remains therefore questionable.
The RGD-mediated cell adhesion to K5IVa was apparently
as strong as to laminin-1 which is mainly mediated by K6L1
and some other integrins not involved in RGD recognition
[19]. Cell adhesion to laminin-10/11, however, is about
10-fold stronger and can be inhibited by antibodies against
L1, K3 and K6 integrin subunits [5,6,13]. This strongly indi-
cated that other domains presumably derived from the C-ter-
minal region of the K5 chain provide stronger cell-adhesive
epitopes than K5IVa. As discussed below, it seems likely that
recognition of K5IVa by other integrins may be mainly re-
quired for mediating other activities such as cell migration.
Fig. 4. Indirect immuno£uorescence staining with a⁄nity-puri¢ed
antibodies against K5IVa of kidney (top) and skeletal muscle (bot-
tom) from adult mice. Bar: 50 Wm.
Table 2
Contents of laminin K5 chain in EDTA/detergent extracts of adult
mouse tissues
Tissue K5IVa assay K1VI/V assay K2VI/V assay
Placenta 159 484 10
Heart 23 1 237
Skeletal muscle 3 6 1 140
Lung 21 2 27
Kidney 28 78 21
Thymus 6 2 16
Skin 4 3 11
Contents (pmol/g wet tissue) were determined by radioimmuno-inhi-
bition assay speci¢c for K5IVa and were compared to the contents
of laminin K1 and K2 chains determined recently (T. Sasaki, R. Gil-
tay, U. Talts, R. Timpl and J.F. Talts, submitted) by similar assays
with recombinant K1VI/V and K2VI/V. The values represented the
sum of EDTA and detergent extracts, which, as shown previously,
solubilize 71^92% of the K1 and K2 chains.
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Antibodies against domain K5IVa were used for the quan-
titation of K5 chains in adult mouse tissue extracts and dem-
onstrated particularly high concentrations in placenta, kidney,
heart and lung amounting to 10^80% of the levels of K1 or K2
chain. This agreed with a strong K5 mRNA expression in the
same tissues exceeding distinctly those of K1 and K2 mRNA
[4]. Such large di¡erences were, however, not detected by the
radioimmunoassay indicating distinct di¡erences in the trans-
lation e⁄ciency or stability of mRNAs encoding di¡erent
laminin K chains. Immunohistology with the K5IVa antibody
con¢rmed previous data [4,7,9^11] by showing a distinct stain-
ing of various renal and alveolar basement membranes and of
capillary and larger vessel walls. In heart and muscle staining
was restricted to the vessels which together with the radio-
immunoassay data suggested a particularly high K5 chain con-
tent in these structures.
The strong deposition of K5-containing laminins in vessel
walls together with the ability to bind RGD-dependent integ-
rins suggests a role for such interactions during cell migration,
angiogenesis and the ¢nal conversion into a stable, non-leaky
neovasculature [35]. Similar activities were already shown for
KVL3 and KVL5 integrins by inhibition studies with monoclo-
nal antibodies [36^38]. The extracellular ligands involved have
so far not been identi¢ed and could include laminins-10/11, as
shown for K5 knock-out mice which fail to vascularize renal
glomeruli [12]. Interestingly, one of the inhibiting antibodies
[37] was also shown here to block substantially K5IVa-medi-
ated cell adhesion (P1F6, see Table 1). Further studies will,
however, be required to show that adhesion-blocking antibod-
ies against K5IVa produce a similar inhibition of angiogenesis.
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